TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03590613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772
Description: GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route
Study: NCT01181024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5303253
Description: Cohorts receiving single ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5303253
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5303253
Description: Multiple doses
Study: NCT02546089

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Blood Injection
Description: ultrasound-guided autologous blood injection procedure
Study: NCT03590613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772
Description: GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
Study: NCT03541265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor block protocol
Description: Adductor block using Exparel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peri-articular injection protocol
Description: peri-articular injection using Exparel
Study: NCT02576288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: anti-inflammatory properties

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No anti-inflammatory properties
Study: NCT02546089

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Structured rehabilitation programme
Description: (this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured rehabilitation programme
Description: (this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
Study: NCT02024620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation plus mobile app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard behavioral activation
Study: NCT03006159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0534
Study: NCT02546089

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dry needling injection
Description: (this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry needling injection
Description: (this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
Study: NCT00069992

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total body irradiation of 450cGy as a single dose, day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30mg/m2 Day -5 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: Campath 1H dosing as per institutional SOPs Day -5 to -2
Study: NCT01441011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group phone counseling
Description: Bi-weekly phone counseling sessions from 6 - 18 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter
Description: Bi-weekly newsletter mailings from 6 - 18 months
Study: NCT04595877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyrone administration
Description: Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain assessment
Description: Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 no pain to point 10 unbearable pain).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pain assessment
Description: Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 no pain to point 10 unbearable pain).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: beta-endorphin immunoreactivity
Description: Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: beta-endorphin immunoreactivity
Description: Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Placebo in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
Study: NCT01283308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
Study: NCT04311398

Intervention type: DIAGNOSTIC_TEST
Intervention: New QIAstat-Dx fully automatic multiple PCR detection platform
Description: We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients
Study: NCT03006159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0534
Study: NCT03618940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge and Attitude on burn prevention
Description: 1.Introduction to Home Safety~2 Fire Safety \& Burn Safety (Cooking Safety, Safety around Motorcycle Exhaust \&First Aid for Minor Burns~3 Electrical Safety (Safety around Electrical \& Appliances \& Outlets)~4 Firecrackers Safety (Safety around Firecrackers \& Open Flames)~5. Escaping from Fire (Escaping from Fire, Calling for Help, Stop, Drop \& Roll, Emergency Calling Number (By Fire Department Kuala Lumpur), Show equipment/gear that firefighters use, Demonstrate how to use the fire extinguisher, Crawl low in smoke
Study: NCT01744717

Intervention type: OTHER
Intervention: Pain measurement
Description: Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.~The procedures to be studied are the following:~* TURNING / POSITIONING (moving side to side or up or down in bed)~* ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)~* NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)
Study: NCT04247126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5609
Description: An oral CDK7 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5609
Description: An oral CDK7 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5609
Description: An oral CDK7 Inhibitor
Study: NCT03006159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT05422677

Intervention type: DRUG
Intervention: Hanmi Tams® Capsule
Description: Hanmi Tams®, Once daily administered per the locally approved product information
Study: NCT04247126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5609
Description: An oral CDK7 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Estrogen receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nucleoside metabolic inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nucleoside metabolic inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Taxane-type chemotherapy
Study: NCT01754298

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retro-articular drilling
Description: * Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.~* Use a 0.045 K-wire for drilling.~* Minimum of 8 wire passes per square centimeter with no maximum number of wire passes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-articular drilling
Description: * Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)~* Use a 0.045 K-wire for drilling~* A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter
Study: NCT02371200

Intervention type: DEVICE
Intervention: Brain Sentinel Seizure Detection and Warning System
Description: The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.
Study: NCT02469415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Part 1: Pacritinib 200 mg taken by mouth twice daily.~Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacitidine
Description: Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
Study: NCT01650415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: twice a week for 1 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo erythropoietin
Description: twice a week for 1 month
Study: NCT02401997

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sexual abstinence
Description: The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sexual abstinence
Description: The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
Study: NCT00554658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
Study: NCT00697437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 70mg q3wx 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 70mg q3wx 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
Study: NCT02401997

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sexual abstinence
Description: The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
Study: NCT03080870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art
Description: Multicomponent art intervention
Study: NCT01987219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol-sulphate
Description: Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium-bromide
Description: Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Saline solution 3 cc NA
Study: NCT03037541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carac Cream
Description: Carac Cream will be used once daily for seven consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cetaphil cream
Description: Placebo Cetaphil Cream will be used once daily for seven consecutive days
Study: NCT02154685

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Retrieval-Extinction
Description: A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-Retrieval Extinction
Description: Neutral cue exposure.
Study: NCT04523090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide (NTZ) is licensed in the USA for treatment of diarrhoea caused by Cryptosporidium parvum and Giardia lamblia. NTZ is a pro-drug for tizoxanide, which also has broad spectrum antiviral properties, has many viral indications and shows promising pharmacodynamics against Coronaviridae. NTZ was identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. In vitro studies evaluating tizoxanide, the active circulating metabolite of NTZ, inhibits the replication of broad range of influenza A and B, HIN1, H3N2, H3N2V, H3N8, H5N9, H7N1 and oseltamivir resistant strain and coronaviruses . It has been shown to have anti-viral activity against several viruses including Ebola, hepatitis B and C, rotavirus and norovirus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills with no active ingredient.
Study: NCT03895996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVT001
Description: autologous dendritic cell therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study: NCT01948128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.
Study: NCT04300595

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combination of General anesthesia and local anesthesia in dacryocystorhinostomy surgery
Description: all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).~In both groups, general anesthesia was induced with 2 mg/kg propofol and tracheal intubation was facilitated by 0.1 mg/kg cisatracurium. All patients underwent mechanical ventilation with 100% oxygen. Anesthesia was maintained with isoflurane, and muscle relaxation was provided by an injection of cisatracurium 0.02 mg/kg every 20 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combination of General anesthesia and local anesthesia in dacryocystorhinostomy surgery
Description: all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).~In both groups, general anesthesia was induced with 2 mg/kg propofol and tracheal intubation was facilitated by 0.1 mg/kg cisatracurium. All patients underwent mechanical ventilation with 100% oxygen. Anesthesia was maintained with isoflurane, and muscle relaxation was provided by an injection of cisatracurium 0.02 mg/kg every 20 minutes.
Study: NCT04424017

Intervention type: BIOLOGICAL
Intervention: Specific anti-SARS-CoV-2 antibodies
Description: A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.~All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA).

Intervention type: BIOLOGICAL
Intervention: Specific anti-SARS-CoV-2 antibodies
Description: A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.~All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA).

Intervention type: BIOLOGICAL
Intervention: Specific anti-SARS-CoV-2 antibodies
Description: A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.~All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA).
Study: NCT02032966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical
Description: Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical
Description: Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical
Description: Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays.
Study: NCT04521465

Intervention type: DEVICE
Intervention: NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters)
Description: Eye drops
Study: NCT00946712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT00994955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: selective retina therapy (SRT)
Description: laser treatment
Study: NCT00853723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone related protein (1-36)
Description: PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone related protein(1-36)
Description: PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid hormone (1-34)
Description: PTH(1-34)20 micrograms subcutaneously administered daily for 3 months